Two injections of durvalumab, given 15 days apart, were followed by a major tumor response in about 11% of patients in a small study at Gustave Roussy in Villejuif, France. One patient, aged 31, had no remaining cancer cells in the tissue removed during surgery.

The findings offer an early look at whether immunotherapy might help some people with small, early-stage triple-negative breast cancer. This cancer type lacks hormone receptors and excess HER2, so hormone treatments and drugs that target HER2 do not work against it. Its outlook is often less favorable than that of other breast cancers. For stage I tumors, chemotherapy before or after surgery remains the usual treatment when it is needed.

The study, called POP-DURVA, tested whether a brief course of durvalumab could trigger an immune response before patients began standard care. Durvalumab is an immunotherapy drug that blocks PD-L1, a protein cancers can use to evade immune attack. The trial enrolled 78 people with stage I triple-negative breast cancer. Their tumors measured no more than 2 centimeters, there was no clinically detectable cancer in nearby lymph nodes, and tests showed at least 5% tumor-infiltrating lymphocytes—immune cells already present in the tumor.

Each patient received two injections, 15 days apart, with no chemotherapy during that short course. Doctors then assessed whether patients could go straight to surgery or needed additional chemotherapy. About 11% had a major pathological response, meaning the amount of cancer had fallen substantially. In one striking case, surgeons found no remaining tumor cells in the breast tissue and lymph nodes removed from a 31-year-old patient.

Researchers also saw changes in the tumors’ immune environment after treatment. In several patients, immune cells became more active within the tumor. The analyses found increases in tumor-infiltrating lymphocytes and in tertiary lymphoid structures, organized groups of immune cells that help coordinate an attack on cancer. These findings may help researchers understand why some tumors respond to immunotherapy while others resist it.

The results, presented at the European Society for Medical Oncology meeting, are an early signal, not proof that durvalumab can replace chemotherapy. POP-DURVA was a small, single-arm phase 2 study, meaning all participants received the drug and there was no comparison group. It was designed to explore activity and biology, not to change treatment guidelines. The researchers’ longer-term goal is to find out whether some patients can safely avoid treatments they may not need, while maintaining effective care.

Dr. Joana Ribeiro said some people with localized stage I disease receive chemotherapy even though they may not benefit from it. The study points to a possible way to identify patients whose tumors are especially sensitive to immunotherapy. Larger studies and further follow-up will be needed before doctors can know whether this approach can safely reduce treatment for anyone.